PortfoliosLab logoPortfoliosLab logo
AGX vs. AXSM
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AGX vs. AXSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Argan, Inc. (AGX) and Axsome Therapeutics, Inc. (AXSM). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AGX achieves a 105.22% return, which is significantly higher than AXSM's 39.71% return. Over the past 10 years, AGX has underperformed AXSM with an annualized return of 35.01%, while AXSM has yielded a comparatively higher 44.70% annualized return.


AGX

1D
2.89%
1M
-10.87%
YTD
105.22%
6M
101.00%
1Y
190.56%
3Y*
154.34%
5Y*
71.15%
10Y*
35.01%

AXSM

1D
0.55%
1M
8.44%
YTD
39.71%
6M
72.21%
1Y
140.16%
3Y*
50.48%
5Y*
30.90%
10Y*
44.70%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AGX vs. AXSM - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AGX
Argan, Inc.
105.22%130.61%198.31%30.24%-2.01%-11.64%19.15%8.62%-14.32%-34.26%
AXSM
Axsome Therapeutics, Inc.
39.71%115.86%6.31%3.19%104.16%-53.63%-21.18%3,565.25%-49.64%-17.04%

Correlation

The correlation between AGX and AXSM is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.14

Correlation (5Y)
Calculated over the trailing 5-year period

0.13

Correlation (10Y)
Calculated over the trailing 10-year period

0.17

Correlation (All Time)
Calculated using the full available price history since Nov 19, 2015

0.17

Fundamentals

Market Cap

AGX:

$9.11B

AXSM:

$13.06B

EPS

AGX:

$11.38

AXSM:

-$3.74

PS Ratio

AGX:

8.72

AXSM:

18.13

PB Ratio

AGX:

19.24

AXSM:

239.33

Total Revenue (TTM)

AGX:

$1.04B

AXSM:

$708.24M

Gross Profit (TTM)

AGX:

$217.93M

AXSM:

$655.82M

EBITDA (TTM)

AGX:

$163.99M

AXSM:

-$172.72M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AGX vs. AXSM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AGX
AGX Risk / Return Rank: 9494
Overall Rank
AGX Sharpe Ratio Rank: 9494
Sharpe Ratio Rank
AGX Sortino Ratio Rank: 9292
Sortino Ratio Rank
AGX Omega Ratio Rank: 9090
Omega Ratio Rank
AGX Calmar Ratio Rank: 9696
Calmar Ratio Rank
AGX Martin Ratio Rank: 9797
Martin Ratio Rank

AXSM
AXSM Risk / Return Rank: 9797
Overall Rank
AXSM Sharpe Ratio Rank: 9797
Sharpe Ratio Rank
AXSM Sortino Ratio Rank: 9797
Sortino Ratio Rank
AXSM Omega Ratio Rank: 9696
Omega Ratio Rank
AXSM Calmar Ratio Rank: 9696
Calmar Ratio Rank
AXSM Martin Ratio Rank: 9797
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AGX vs. AXSM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Argan, Inc. (AGX) and Axsome Therapeutics, Inc. (AXSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AGXAXSMDifference
Sharpe ratioReturn per unit of total volatility

-0.78

Sortino ratioReturn per unit of downside risk

-1.48

Omega ratioGain probability vs. loss probability

1.41

1.57

-0.16

Calmar ratioReturn relative to maximum drawdown

7.68

7.62

+0.06

Martin ratioReturn relative to average drawdown

21.89

22.44

-0.55

AGX vs. AXSM - Sharpe Ratio Comparison

The current AGX Sharpe Ratio is 2.59, which is comparable to the AXSM Sharpe Ratio of 3.37. The chart below compares the historical Sharpe Ratios of AGX and AXSM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AGX vs. AXSM - Drawdown Comparison

The maximum AGX drawdown since its inception was -94.37%, which is greater than AXSM's maximum drawdown of -86.65%. Use the drawdown chart below to compare losses from any high point for AGX and AXSM.


Loading charts...

Drawdown Indicators


AGXAXSMDifference

Max Drawdown

Largest peak-to-trough decline

-94.37%

-86.65%

-7.72%

Max Drawdown (1Y)

Largest decline over 1 year

-24.96%

-18.50%

-6.46%

Max Drawdown (3Y)

Largest decline over 3 years

-43.75%

-36.45%

-7.30%

Max Drawdown (5Y)

Largest decline over 5 years

-43.75%

-72.91%

+29.16%

Max Drawdown (10Y)

Largest decline over 10 years

-54.61%

-81.26%

+26.65%

Current Drawdown

Current decline from peak

-13.39%

0.00%

-13.39%

Average Drawdown

Average peak-to-trough decline

-48.33%

-39.47%

-8.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.78%

6.31%

+2.47%

Volatility

AGX vs. AXSM - Volatility Comparison

Argan, Inc. (AGX) has a higher volatility of 18.53% compared to Axsome Therapeutics, Inc. (AXSM) at 9.24%. This indicates that AGX's price experiences larger fluctuations and is considered to be riskier than AXSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AGXAXSMDifference

Volatility (1M)

Calculated over the trailing 1-month period

18.53%

9.24%

+9.29%

Volatility (6M)

Calculated over the trailing 6-month period

54.47%

33.14%

+21.33%

Volatility (1Y)

Calculated over the trailing 1-year period

74.07%

41.89%

+32.18%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

50.95%

70.25%

-19.30%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

45.88%

90.53%

-44.65%

Dividends

AGX vs. AXSM - Dividend Comparison

AGX's dividend yield for the trailing twelve months is around 0.29%, while AXSM has not paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
AGX
Argan, Inc.
0.29%0.52%0.93%2.24%2.71%1.94%7.31%2.49%1.98%4.44%1.42%2.16%
AXSM
Axsome Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

AGX vs. AXSM - Financials Comparison

This section allows you to compare key financial metrics between Argan, Inc. and Axsome Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M20222023202420252026
290.95M
191.20M
(AGX) Total Revenue
(AXSM) Total Revenue
Values in USD except per share items

AGX vs. AXSM - Profitability Comparison

The chart below illustrates the profitability comparison between Argan, Inc. and Axsome Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%40.0%60.0%80.0%100.0%20222023202420252026
21.0%
92.3%
Portfolio components
AGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a gross profit of 61.11M and revenue of 290.95M. Therefore, the gross margin over that period was 21.0%.

AXSM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a gross profit of 176.48M and revenue of 191.20M. Therefore, the gross margin over that period was 92.3%.

AGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported an operating income of 45.40M and revenue of 290.95M, resulting in an operating margin of 15.6%.

AXSM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported an operating income of -63.36M and revenue of 191.20M, resulting in an operating margin of -33.1%.

AGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Argan, Inc. reported a net income of 46.06M and revenue of 290.95M, resulting in a net margin of 15.8%.

AXSM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a net income of -64.54M and revenue of 191.20M, resulting in a net margin of -33.8%.


Frequently Asked Questions


AGX and AXSM have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AGX has higher volatility (18.53%) compared to AXSM (9.24%). In terms of maximum drawdown, AGX dropped -94.37% vs AXSM's -86.65%.

AXSM currently has the higher Sharpe Ratio (3.37 vs 2.59), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AGX and AXSM

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer